CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
Intranasal Oxytocin (Trade name: Syntocinon)drug
Likely dose
Intranasal Oxytocin (Trade name: Syntocinon) 24 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01417026
NCT01417026Phase 2Completed
CompareCT.gov

Promoting Social Perceptual Learning With Oxytocin in Autism

Robert Schultz·interventional·Posted Aug 16, 2011·Updated Mar 30, 2017

In Brief

A Phase 2 clinical trial evaluating Intranasal Oxytocin (Trade name: Syntocinon) for Autism Spectrum Disorders. Completed, enrolled 36 participants across 1 site.

Detailed Summary

The main objective of this study is to determine the safety and therapeutic potential of intranasal oxytocin in children and adolescents with autism spectrum disorder (ASD) when paired with a computer game intervention that is designed to enhance face perception skills.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutism Spectrum Disorders
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 16, 2011
Enrollment StartSep 1, 2011
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 14.9 years ago

Interventions

Intranasal Oxytocin (Trade name: Syntocinon)drug

This is a double-blind placebo-controlled trial of intranasal oxytocin in children and adolescents with ASD. Subjects will be randomized to 24 IU intranasal oxytocin or placebo for a 5 day period with concomitant game play of computer games, which are designed to enhance face perception skills. Measures of social function and cognition will be administered before and after the intervention period.